Graf Acquisition Corp. IV completed a merger with NKGen Biotech, Inc., resulting in the formation of New NKGen. The merger was approved by Graf's stockholders and resulted in the exchange of shares and options between the two companies. The filing also includes information about financing agreements, lock-up agreements, and other related party transactions.